ArticlePharmacoEconomics2023
Catalogues of EQ-5D-3L Health-Related Quality of Life Scores for 199 Chronic Conditions and Health Risks for Use in the UK and the USA.
Article in PharmacoEconomics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The economic burden of anesthetic-related adverse events: a systematic review and empirical analysis.BMC anesthesiology · 2025Pooled it
- A pilot randomised controlled trial of the Tailored Intervention for people with moderate-to-severe Chronic Obstructive Pulmonary Disease and Co-morbidities delivered by Pharmacists and Consultant respiratory Physicians (TICC-PCP).NPJ primary care respiratory medicine · 2025Trial
- How eight health risks and chronic conditions relate: identifying associations and profiling characteristics of multiple health risk factors among 14 disease groups and 30 common chronic conditions in Denmark.Scandinavian journal of public health · 2026Article
- Cost-Effectiveness Analysis of Bariatric Surgery and Pharmacological Treatments for People with Obesity and Type 2 Diabetes Mellitus.Obesity surgery · 2026Article
- Catalogue of eight psychological and behavioural health risks and related disparities among 199 chronic conditions in Denmark.Scandinavian journal of public health · 2026Article
- Lung Cancer Screening in a Population from Northeast Italy Exposed to Both Asbestos and Smoking: A Cost-Effectiveness Analysis.Journal of clinical medicine · 2026Article
- Cost-Effectiveness Modelling of Multiple System Atrophy for Early Health Technology Assessment.PharmacoEconomics - open · 2026Article
- Impact of disease activity on quality of life and EQ-5D-3L score in myasthenia gravis: results from the Swedish MG registry.Journal of neurology · 2025Article
- A Method for Adjusting EQ-5D-3L Health State Utilities for Cross-Country Use: Application of a Novel US-to-UK Utility Mapping Approach.ClinicoEconomics and outcomes research : CEOR · 2025Article
- A China-Based Cost-Effectiveness Analysis of Novel Oral Anticoagulants versus Warfarin in Patients with Left Ventricular Thrombosis.Risk management and healthcare policy · 2024Article
- Cost-Effectiveness of Timely Surgery and Timely Inpatient Rehabilitation for the Management of Hip Fracture.JB & JS open accessArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundHealth-related quality of life (HRQoL) measures are essential in economic evaluation, but sometimes primary sources are unavailable, and information from secondary sources is required. Existing HRQoL UK/US catalogues are based on earlier diagnosis classification systems, amongst other issues. A recently published Danish catalogue merged EQ-5D-3L data from national health surveys with national registers containing patient information on ICD-10 diagnoses, healthcare activities and socio-demographics.
aimsTo provide (1) UK/US EQ-5D-3L-based HRQoL utility population catalogues for 199 chronic conditions on the basis of ICD-10 codes and health risks and (2) regression models controlling for age, sex, comorbidities and health risks to enable predictions in other populations.
methodsUK and US EQ-5D-3L value sets were applied to the EQ-5D-3L responses of the Danish dataset and modelled using adjusted limited dependent variable mixture models (ALDVMMs).
resultsUnadjusted mean utilities, percentiles and adjusted disutilities based on two ALDVMMs with different control variables were provided for both countries. Diseases from groups M, G, and F consistently had the smallest utilities and the largest negative disutilities: fibromyalgia (M797), sclerosis (G35), rheumatism (M790), dorsalgia (M54), cerebral palsy (G80-G83), post-traumatic stress disorder (F431), dementia (F00-2), and depression (F32, etc.). Risk factors, including stress, loneliness, and BMI30+, were also associated with lower HRQoL.
conclusionsThis study provides comprehensive catalogues of UK/US EQ-5D-3L HRQoL utilities. Results are relevant in cost-effectiveness analysis, for NICE submissions, and for comparing and identifying facets of disease burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.